Search

Displaying results 4771 - 4780 of 4822 in total
  1. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available.

  2. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.

  3. Drug

    Morphine glucuronide

    go.drugbank.com/drugs/DB06409
    Investigational

  4. Drug

    MKC1106-PP

    go.drugbank.com/drugs/DB06030
    Experimental

    MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM. The plasmid portion is a recombinant plasmid expressing segments of the 2 target antigens, PRAME and PSMA. MKC1106-PP...

  5. Drug

    Uric acid

    go.drugbank.com/drugs/DB08844
    Investigational

    As a therapeutic agent, it is known that uric acid is increased in response to oxidative stress, and as such, uric acid acts as an antioxidant.

  6. Drug

    Abafungin

    go.drugbank.com/drugs/DB06395
    Experimental

  7. Drug

    Ulevostinag

    go.drugbank.com/drugs/DB14721
    Investigational

    Upon intratumoral (IT) administration, STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear

  8. Drug

    CRx-401

    go.drugbank.com/drugs/DB05775
    Experimental

    It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent.

  9. Drug

    GC-373

    go.drugbank.com/drugs/DB15797
    Experimental

    It is an inhibitor of M<sup>pro</sup> (otherwise known as 3CL<sup>pro</sup>), a viral encoded protease that cleaves and activates functional proteins involved in viral replication and transcription[A219036

  10. Drug

    MYR-101

    go.drugbank.com/drugs/DB17075
    Investigational

    It is caused by a mutation in the aspartoacylase gene (_ASPA_), which leads to a deficiency of the aspartoacylase enzyme (ASPA).